Comparing a new biopsy needle to standard methods for prostate cancer detection
Comparison of BARD Max Core 18g Needle With Uro1 SUREcore 18g Needle in Targeted Prostate Biopsies
This study is testing a new biopsy needle to see if it can help doctors find prostate cancer better than the usual methods for men who need a prostate biopsy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | University of California, Davis Academic / other |
| Locations | 1 site (Sacramento, California) |
| Trial ID | NCT06907446 on ClinicalTrials.gov |
What this trial studies
This study evaluates a novel biopsy needle system designed for transperineal prostate biopsies, aiming to enhance the detection of prostate cancer. The new SureCore needle is expected to provide more intact tissue cores and increase the amount of tissue collected per sample compared to standard needles. By comparing the effectiveness of this new needle against traditional methods, the research seeks to determine if it can improve cancer detection rates and characterization. Participants will be men over 18 years old who are scheduled for a prostate biopsy.
Who should consider this trial
Good fit: Ideal candidates for this study are men over the age of 18 who are scheduled to undergo a prostate biopsy.
Not a fit: Patients who are unable to consent or have significant comorbidities that may interfere with the study's objectives may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved detection and characterization of prostate cancer, potentially enhancing patient outcomes.
How similar studies have performed: While this approach is innovative, similar studies have not been widely reported, indicating that this may be a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient older than age of 18 undergoing prostate biopsy Exclusion Criteria: * Unable to consent * Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives * Prisoners
Where this trial is running
Sacramento, California
- UC Davis Departments of Urologic Oncology — Sacramento, California, United States (Recruiting)
Study contacts
- Study coordinator: Marc Dall'Era, MD
- Email: mdallera@ucdavis.edu
- Phone: 916-734-2893
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.